Antares pharma inc.
On April 12, 2022, Antares Pharma, Inc., a Delaware corporation (the “ Company ”), entered into an Agreement and Plan of Merger (the “ Merger Agreement ”) with Halozyme Therapeutics, Inc., a Delaware corporation (“ Halozyme ”), and Atlas Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Halozyme ...
Pipeline :: Antares Pharma. Halozyme has completed its acquistion of Antares Pharma, creating a leading drug delivery business. View details here. Nov 10, 2022 · XYOSTED (testosterone enanthate) injection is an androgen indicated for testosterone replacement therapy in adult males for conditions associated with a deficiency or absence of endogenous testosterone ( 1 ). Safety and efficacy of XYOSTED in males less than 18 years old have not been established ( 1, 8.4 ). Invisible Fence Inc. is a leading provider of innovative pet containment and lifestyle solutions. With over 40 years of experience, Invisible Fence Inc. has developed products that are designed to keep pets safe and secure in their own yard...Antares Pharma, Inc. is a specialty pharmaceutical company. The Company is focused primarily on the development and commercialization of pharmaceutical products and technologies that address patient needs in targeted therapeutic areas. The Company develops, manufactures, and commercializes, for itself …
SALT LAKE CITY - Lipocine Inc. (NASDAQ: LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, announced it has entered into an exclusive licensing agreement with Antares Pharma, Inc. to commercialize TLANDO in the United States.TLANDO is an oral testosterone product for …
Lipocine Inc. (NASDAQ: LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today announced it has entered into an exclusive licensing agreement with Antares Pharma, Inc. to commercialize TLANDO in the United States. TLANDO is an oral testosterone product for testosterone replacement therapy ("TRT") in ...
Address Medical Inquiries to: Antares Pharma, Inc. Medical Communications 100 Princeton South, Suite 300 Ewing, NJ 08628, 1-855-Otrexup (1-855-687-3987) Nonclinical Toxicology. No Information provided. Use In Specific Populations Pregnancy Risk Summary. Based on published reports and methotrexate’s …Our multi-use, disposable pen injector complements our portfolio of single-use pressure assisted auto injector devices. The disposable pen injector device is designed to deliver drugs by injection through needles from multi-dose cartridges. Our disposable pen injector is designed for chronic conditions such as diabetes, which require daily ... Antares Pharma, Inc. is a specialty pharmaceutical company focused primarily on the development and commercialization of self-administered injectable pharmaceutical products using advanced drug ...SAN DIEGO, May 24, 2022 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced the successful completion of its acquisition of …
EWING, N.J., March 29, 2022 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ: ATRS) (the “Company”), a specialty pharmaceutical company, today announced that …
Through our recent acquisition of Antares Pharma, Inc. (“Antares”), we also develop, manufacture and commercialize, for ourselves or with our partners, drug-device combination products using our advanced auto-injector technologies that are designed to provide commercial or functional advantages such as convenience, improved tolerability, …
Mar 29, 2022 · Follow. EWING, N.J., March 29, 2022 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ: ATRS) (the “Company”), a specialty pharmaceutical company, today announced that the U.S. Food and Drug ... Halozyme Inc. is an Equal Employment Opportunity (EEO) employer. It is the policy of the Company to provide equal employment opportunities to all qualified applicants without regard to race, color, religion, sex, sexual orientation, gender identity, national origin, age, protected veteran or disabled status, or genetic information. Antares Pharma, Inc. (“Antares,” “we,” “our,” “us” or the “Company”) is an emerging, specialty pharmaceutical company that focuses on developing and commercializing self-administered parenteral pharmaceutical products and technologies. Delaware . 1-32302 . 41-1350192 (State or Other Jurisdiction. of Incorporation) (Commission. File Number) (I.R.S. Employer. Identification No.) 100 Princeton South ...Antares Pharma, Inc. (Name of Issuer) Common Stock, $0.01 par value per share (Title of Class of Securities) 036642106 (CUSIP Number) December 31, 2021 (Date of event which requires filing of this statement) Check the appropriate box to designate the rule pursuant to which this Schedule 13G is filed: x: Rule 13d-1(b) ¨ Rule 13d-1(c) ¨ Rule ...
Plaintiff–Appellant Antares Pharma, Inc. (“Antares”) appeals from a decision of the United States District Court for the District of Delaware denying Antares' motion for preliminary injunction. Antares seeks to enjoin alleged infringement of claims 31, 34, 35, and 37 of a reissue patent, RE44, 846 (“the '846 patent”).Antares Pharma, Inc. is a specialty pharmaceutical company focused primarily on the development and commercialization of self-administered injectable pharmaceutical products using advanced drug ...References: 1. NOCDURNA prescribing information: Ferring Pharmaceuticals Inc. Please see Prescribing Information including important safety information and boxed warning. * Source: Bloomberg/Symphony Health Solutions 0 100 200 300 400 500 600 700 800 NOCDURNA® Monthly TRx* NRx Refills XYOSTED is a prescription medicine that contains testosterone. XYOSTED is used to treat adult men who have low or no testosterone due to certain medical conditions. It is not known if XYOSTED is safe and effective for use in children younger than 18 years old. Improper use of XYOSTED may affect bone growth in children.Antares Pharma, Inc. is a pharmaceutical technology company focused primarily on the development and commercialization of self-administered injectable pharmaceutical products using advanced drug ...Minnetonka, Minnesota (763) 475-7700 12500 Whitewater Drive Minnetonka, MN 55343 USA
ANTARES PHARMA, INC. (Exact name of registrant specified in its charter) _____ Delaware: 1-32302: 41-1350192 (State or Other Jurisdiction. of Incorporation) (Commission. File Number) (I.R.S. Employer. Identification No.) 100 Princeton South, Suite 300, Ewing, ...Halozyme Therapeutics Inc. agreed to a nearly $1 billion deal to buy specialty pharmaceutical company Antares Pharma Inc. in a move that will deepen its focus on …
Pipeline :: Antares Pharma. Halozyme has completed its acquistion of Antares Pharma, creating a leading drug delivery business. View details here.Antares Pharma, Inc. (NASDAQ:ATRS) issued its quarterly earnings data on Thursday, November, 4th. The specialty pharmaceutical company reported $0.03 EPS for the quarter, meeting the consensus estimate of $0.03. The specialty pharmaceutical company earned $48.19 million during the quarter, compared to the consensus estimate of $48.52 million.Antares Pharma, Inc. is a specialty pharmaceutical company focused primarily on the development and commercialization of self-administered injectable pharmaceutical products using advanced drug ...Antares Pharma, Inc. is a specialty pharmaceutical company. The Company is focused primarily on the development and commercialization of pharmaceutical products and technologies that address patient needs in targeted therapeutic areas. The Company develops, manufactures, and commercializes, for itself …Antares Pharma, Inc. is a specialty pharmaceutical company focused primarily on the development and commercialization of pharmaceutical products and technologies that address unmet needs in ...As previously disclosed, on February 28, 2014, Antares Pharma, Inc. (“Antares”) sued Medac Pharma, Inc. (“Medac”) and its foreign parent, medac GmbH, in the United States District Court for the District of Delaware alleging infringement. Antares is asserting four patents. On March 14, 2014, Antares filed a motion for preliminary injunction seeking to …
Oct 18, 2021 · Lipocine Inc. (NASDAQ: LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today announced it has entered into an exclusive licensing agreement with Antares Pharma, Inc. to commercialize TLANDO in the United States. TLANDO is an oral testosterone product for testosterone replacement therapy ("TRT") in ...
Nov 4, 2021 · Antares Pharma, Inc. is a specialty pharmaceutical company focused primarily on the development and commercialization of self-administered injectable pharmaceutical products using advanced drug ...
Antares Pharma, Inc. is a specialty pharmaceutical company focused primarily on the development and commercialization of self-administered injectable pharmaceutical products using advanced drug ...May 24, 2022 ... ... Antares Pharma, Inc., a specialty pharmaceutical company focused primarily on the development and commercialization of pharmaceutical ...EWING, N.J., Dec. 15, 2021 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ: ATRS) (the “Company”), a specialty pharmaceutical company, today announced the …Antares Pharma, Inc. is a pharmaceutical technology company focused primarily on the development and commercialization of self-administered injectable pharmaceutical products using advanced drug ...Company profile page for Antares Pharma Inc including stock price, company news, press releases, executives, board members, and contact informationNov 10, 2022 · XYOSTED (testosterone enanthate) injection is an androgen indicated for testosterone replacement therapy in adult males for conditions associated with a deficiency or absence of endogenous testosterone ( 1 ). Safety and efficacy of XYOSTED in males less than 18 years old have not been established ( 1, 8.4 ). Halozyme Therapeutics Inc (NASDAQ: HALO) will acquire Antares Pharma Inc (NASDAQ: ATRS) for $5.60 per share, valuing Antares at approximately 0 million. The transaction is expected to be accretive ...using Antares auto injector technology •~75% of all commercial lives covered • 18 Orange Book listed patents extending to 2038 •FY 2021 revenue of $62.2M, up 34% year-over-year XYOSTED® TLANDO™ •Oral testosterone replacement therapy (TRT) •Granted FDA approval on March 28, 2022 and commercially launched in June 2022 •2X/daily ...Antares Pharma, Inc. is a specialty pharmaceutical company. The Company is focused primarily on the development and commercialization of pharmaceutical products and technologies that address patient needs in targeted therapeutic areas.About Antares Pharma . Antares Pharma, Inc. is a specialty pharmaceutical company focused primarily on the development and commercialization of pharmaceutical products and technologies that address patient needs in targeted therapeutic areas. The Company develops, manufactures and commercializes, for itself or with partners, novel therapeutic ...
Antares Pharma, Inc. announced the appointment of Peter Richardson as Executive Vice President, Research and Development and Chief Medical Officer. In this role, Dr. Richardson will oversee the...Antares Pharma Inc (Antares Pharma), a subsidiary of Halozyme Therapeutics Inc, is a specialty pharmaceutical company engaged in the development, …Company Description: Antares Pharma understands antagonism towards needles. The company develops needle-free systems for administering injectable drugs. Its Medi-Jector Vision system, for instance, injects a thin, high-pressure stream of liquid, eliminating the need for a needle.Instagram:https://instagram. aetna dental access savings plan.voois renting better than buyingwhat is the best ambetter plan On April 12, 2022, Antares Pharma, Inc., a Delaware corporation (the “ Company ”), entered into an Agreement and Plan of Merger (the “ Merger Agreement ”) with Halozyme Therapeutics, Inc., a Delaware corporation (“ Halozyme ”), and Atlas Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Halozyme ...Antares Pharma, Inc. is a specialty pharmaceutical company focused primarily on the development and commercialization of self-administered injectable pharmaceutical products using advanced drug ... fintech companies charlotte ncprice of cigna stock Plaintiff–Appellant Antares Pharma, Inc. (“Antares”) appeals from a decision of the United States District Court for the District of Delaware denying Antares' motion for preliminary injunction. Antares seeks to enjoin alleged infringement of claims 31, 34, 35, and 37 of a reissue patent, RE44, 846 (“the '846 patent”).Device Type: Auto-Injector: Dosage Type: Fixed for viscous and aqueous formulations: Injection Volume: 0.2-1.0ml Injection Type: SC or IM: Primary Container: stocks to short right now About Antares Pharma . Antares Pharma, Inc. is a specialty pharmaceutical company focused primarily on the development and commercialization of pharmaceutical products and technologies that address patient needs in targeted therapeutic areas. Antares Pharma, Inc. is a specialty pharmaceutical company focused primarily on the development and commercialization of pharmaceutical products and technologies that address patient needs in ...